Trials / Active Not Recruiting
Active Not RecruitingNCT06779851
A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors
A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Bright Peak Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPT567 | Immunocytokine infusion |
Timeline
- Start date
- 2024-10-15
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2025-01-17
- Last updated
- 2026-02-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06779851. Inclusion in this directory is not an endorsement.